文献速递神经肌肉病

基于Rasch分析的CMT神经病与检查评分在CMT1A中的纵向研究

A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores.
PubMed 文献 · Neurology · 2020-02-11

本研究纳入18个中心的CMT1A患者,采用Rasch分析加权的CMTNS-R和CMTES-R评估临床进展。CMTES-R在2至6年显示显著变化,2年时标准化反应均值较原版CMTES提高55%,且在轻中度患者中最敏感。

要点

  • CMTES-R较原版CMTES对CMT1A病情进展更敏感。
  • CMTES-R在轻中度患者中变化最显著,重度患者未能捕捉进展。
  • CMTES-R 2年标准化反应均值较原版提高55%。

核心结论

  • CMTES-R能反映CMT1A患者随时间的变化,且比原版CMTES更敏感。
  • CMTES-R对轻中度基线病情患者最敏感,对重度CMT1A未能捕捉进展。

研究设计与样本

  • 来自遗传性神经病联盟18个中心的CMT1A患者,2009至2018年评估。
  • 基线CMTNS-R可用517例,CMTES-R可用1177例。

主要发现

  • CMTES-R评分在2至6年较基线显著变化,2年平均变化0.59分,p=0.0004,n=321。
  • 2年时CMTES-R标准化反应均值为0.17,原版CMTES为0.11,提高55%。
  • 基线CMTES-R评分0-9分的轻中度患者2年平均变化1.48分,95%CI 0.99-1.97,p<0.0001。

临床怎么用

  • 在CMT1A临床随访中可优先使用CMTES-R评估轻中度患者的病情进展。

局限性

  • CMTES-R在重度CMT1A患者中未能捕捉病情进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the sensitivity of Rasch analysis-based, weighted Charcot-Marie-Tooth Neuropathy and Examination Scores (CMTNS-R and CMTES-R) to clinical progression in patients with Charcot-Marie-Tooth disease type 1A (CMT1A). METHODS: Patients with CMT1A from 18 sites of the Inherited Neuropathies Consortium were evaluated between 2009 and 2018. Weighted CMTNS and CMTES modified category responses were developed with Rasch analysis of the standard scores. Change from baseline for CMTNS-R and CMTES-R was estimated with longitudinal regression models. RESULTS: Baseline CMTNS-R and CMTES-R scores were available for 517 and 1,177 participants, respectively. Mean ± SD age of participants with available CMTES-R scores was 41 ± 18 (range 4-87) years, and 56% were female. Follow-up CMTES-R assessments at 1, 2, and 3 years were available for 377, 321, and 244 patients. A mixed regression model showed significant change in CMTES-R score at years 2 through 6 compared to baseline (mean change from baseline 0.59 points at 2 years, p = 0.0004, n = 321). Compared to the original CMTES, the CMTES-R revealed a 55% improvement in the standardized response mean (mean change/SD change) at 2 years (0.17 vs 0.11). Change in CMTES-R at 2 years was greatest in mildly to moderately affected patients (1.48-point mean change, 95% confidence interval 0.99-1.97, p < 0.0001, for baseline CMTES-R score 0-9). CONCLUSION: The CMTES-R demonstrates change over time in patients with CMT1A and is more sensitive than the original CMTES. The CMTES-R was most sensitive to change in patients with mild to moderate baseline disease severity and failed to capture progression in patients with severe CMT1A. CLINICALTRIALSGOV IDENTIFIER: NCT01193075.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Fridman V, Sillau S, Acsadi G, et al. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology. 2020. PMID: 32047073. doi:10.1212/WNL.0000000000009035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。